OA  /  E-mail  /    Download   /   中文版         

Search

1

 China National Scientific Instruments
Your location:
Homepage
/
/
Company Activities
05-28

Sinopharm held a video conference on office line work in 2022

In order to further strengthen the office line management of subsidiaries, deploy relevant key tasks, and ensure that various management requirements are in place, on April 20, Sinopharm held a video conference on office line work in 2022. A total of 554 people attended the meeting, including office directors and related office staff of the third-level subsidiaries. Du Jiang, deputy general manager of Sinopharm Instruments, attended the meeting and delivered a speech. The meeting was presided over by Yu Yu, deputy director of the general manager's office (presiding over the work). Du Jiang affirmed the hard work of the company's office line staff at all levels in the past year. He briefly reviewed the achievements of Sinopharm Instruments in 2021, and put forward three requirements for the office line: first, to think about big things, to plan Big things, big things. In 2021, the whole system of Sinopharm equipment has undergone the political inspection of the SASAC Party Committee. Companies at all levels have sorted out and formulated a list of issues and rectification resolutions, which involve important matters in all aspects of the company. Office directors should pay close attention to them and actively promote them in accordance with the rectification requirements. At the forefront of work, be a staff assistant to a good leader. The second is to focus on the key tasks of this year, make overall arrangements, and improve efficiency. In 2022, the office line must continue to promote the standardization and standardization of daily work. In addition, it must actively cooperate with the audit of the National Audit Office and the 7 internal control inspections carried out by the State-owned Assets Supervision and Administration Commission. Office directors must plan ahead, improve the mechanism, and develop creatively. Work. The third is to talk about study, talk about politics, talk about righteousness, and strengthen team building. In recent years, the company has developed rapidly, and management requirements and work procedures have been updated frequently. In the face of new documents and new requirements from superiors, the director of the office must not only communicate correctly, but also earnestly study and understand the contents of the documents, and strive to build an efficient office team. Yu Yu reviewed the key work of the office line in 2021, and deployed the key work in 2022 from the seven aspects of office meeting, system, brand, seal, confidentiality, official documents, and archives, focusing on specific requirements for confidentiality management. Huang Haiying, director of the administration department, explained the company's relevant standards and red line requirements from the aspects of official vehicles, office space, business hospitality, fixed assets, and business travel services. In order to continuously improve the basic management level of subsidiary offices and let subsidiaries understand the latest management requirements of superiors, at the meeting, Wu Lin of the Risk and Operation Management Department of the Headquarters, Song Jingjing, Li Zhuoran, Yuan Yong, Zhang Mian of the General Manager Office, and Wang Xin of the Public Affairs Department , Fan Xiao, and Shu Changning of the Logistics Management Department, respectively, from the work requirements of system "abolition and reformation", brand management and VI use, office meeting process, confidentiality work priorities, lean file management and association joining, cooperation agreement signing, public opinion management, Publicity and training were carried out for subsidiaries in terms of news publicity and engineering construction management. The content of this meeting integrates the management functions of the subsidiary's office line, and provides targeted explanations around the difficulties and problems encountered in daily work, which will surely further strengthen the subsidiary's basic management level and effectively promote the company's health. develop.
03-07

Sinopharm China Bio-Omicron Variant Novel Coronavirus Inactivated Vaccine Obtained Clinical Approval from the State Food and Drug Administration

Sinopharm Sinopharm Group China Biotech introduced the Omicron variant strain from the University of Hong Kong for the first time on the basis of the prototype new crown inactivated vaccine and the completion of the development of beta and delta variant inactivated vaccines in the early stage, December 2021 On the 9th, the research and development of the Austrian strain inactivated vaccine was quickly launched. According to the guiding principles and research and development strategies of the improved new crown vaccine of the State Food and Drug Administration, Sinopharm Group China Biotechnology has completed the screening, passage and expansion of the Austrian strain by using the newly built P3 high-level biosafety laboratory, and established a three-level virus. The seed bank has completed process verification, preparation of multiple batches of large-scale products, quality standard research, safety evaluation in animals and immunogenicity research. titer of neutralizing antibodies. On March 3, 2022, the Beijing Institute of Biology of Sinopharm, Wuhan Institute of Biology and Hong Kong research institutions confirmed the clinical plan and related details. The clinical application materials were submitted to the Hong Kong Department of Health on the 1st, the ethics approval was obtained on April 12th, and the clinical research approval was obtained on April 13th, becoming the world's first inactivated vaccine of Chronomicron strains approved for clinical use. At the same time of Sinopharm, Sinopharm Group Sino Bio began to submit domestic clinical application materials to the Drug Evaluation Center of the State Food and Drug Administration on a rolling basis from January 26 to start the technical review. Sinopharm On April 26, Sinopharm China Bio-Beijing Biological Products Research Institute's Omicron variant new coronavirus inactivated vaccine obtained the clinical approval issued by the State Food and Drug Administration of China. Sinopharm Group China Biotechnology will use a randomized, double-blind, cohort study to conduct a sequential immunization clinical study in people aged 18 and over who have completed 2 or 3 doses of the new crown vaccine to evaluate the efficacy of the new crown virus of the Omicron variant. Safety and immunogenicity of live vaccines. Sinopharm shoulders the political and social responsibilities of a central enterprise. Sinopharm Group China Bio has independently developed 4 new crown diagnostic reagents, 4 new crown specific treatment drugs and successfully developed three technical routes in the three fields of "diagnosable, curable and preventable". The four new crown vaccines have given full play to the role of the national team, main force and pillar of the pharmaceutical industry, created a strategic scientific and technological force to maintain national biosecurity, and promoted Chinese vaccines and therapeutic drugs to benefit the Chinese people and the world.
03-07

Sinopharm held a video conference on office line work in 2022

In order to further strengthen the office line management of subsidiaries, deploy relevant key tasks, and ensure that various management requirements are in place, on April 20, Sinopharm held a video conference on office line work in 2022. A total of 554 people attended the meeting, including office directors and related office staff of the third-level subsidiaries. Du Jiang, deputy general manager of Sinopharm Instruments, attended the meeting and delivered a speech. The meeting was presided over by Yu Yu, deputy director of the general manager's office (presiding over the work). Du Jiang affirmed the hard work of the company's office line staff at all levels in the past year. He briefly reviewed the achievements of Sinopharm Instruments in 2021, and put forward three requirements for the office line: first, to think about big things, to plan Big things, big things. In 2021, the whole system of Sinopharm equipment has undergone the political inspection of the SASAC Party Committee. Companies at all levels have sorted out and formulated a list of issues and rectification resolutions, which involve important matters in all aspects of the company. Office directors should pay close attention to them and actively promote them in accordance with the rectification requirements. At the forefront of work, be a staff assistant to a good leader. The second is to focus on the key tasks of this year, make overall arrangements, and improve efficiency. In 2022, the office line must continue to promote the standardization and standardization of daily work. In addition, it must actively cooperate with the audit of the National Audit Office and the 7 internal control inspections carried out by the State-owned Assets Supervision and Administration Commission. Office directors must plan ahead, improve the mechanism, and develop creatively. Work. The third is to talk about study, talk about politics, talk about righteousness, and strengthen team building. In recent years, the company has developed rapidly, and management requirements and work procedures have been updated frequently. In the face of new documents and new requirements from superiors, the director of the office must not only communicate correctly, but also earnestly study and understand the contents of the documents, and strive to build an efficient office team. Yu Yu reviewed the key work of the office line in 2021, and deployed the key work in 2022 from the seven aspects of office meeting, system, brand, seal, confidentiality, official documents, and archives, focusing on specific requirements for confidentiality management. Huang Haiying, director of the administration department, explained the company's relevant standards and red line requirements from the aspects of official vehicles, office space, business hospitality, fixed assets, and business travel services. In order to continuously improve the basic management level of subsidiary offices and let subsidiaries understand the latest management requirements of superiors, at the meeting, Wu Lin of the Risk and Operation Management Department of the Headquarters, Song Jingjing, Li Zhuoran, Yuan Yong, Zhang Mian of the General Manager Office, and Wang Xin of the Public Affairs Department , Fan Xiao, and Shu Changning of the Logistics Management Department, respectively, from the work requirements of system "abolition and reformation", brand management and VI use, office meeting process, confidentiality work priorities, lean file management and association joining, cooperation agreement signing, public opinion management, Publicity and training were carried out for subsidiaries in terms of news publicity and engineering construction management. The content of this meeting integrates the management functions of the subsidiary's office line, and provides targeted explanations around the difficulties and problems encountered in daily work, which will surely further strengthen the subsidiary's basic management level and effectively promote the company's health. develop.

Contact  

Business cmiczkq@sinopharm.com

Hotline:86-27-84888155 

 

Address:No.666, Gaoxin Avenue, Wuhan East Lake High-Tech Development Zone, Wuhan City,Hubei Province, China Copyright © csimcwh.com All Rights Reserved

   ICP:13017258-1  Power by www.300.cn     SEO    Business license

Address:No.666, Gaoxin Avenue, Wuhan East Lake High-Tech Development Zone, Wuhan City,Hubei Province

China Copyright © csimcwh.com All Rights Reserved

 ICP:13017258-1  Power by www.300.cn  

 China National Scientific Instruments